The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Assessment of the variability of and effect of hormone therapy on circulating tumor cell numbers and androgen receptor expression in patients with prostate cancer.
Noel W Clarke
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Sarah E Marley
Employment or Leadership Position - AstraZeneca
Andrew M. Hughes
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Research Funding - AstraZeneca
Anthony F Nash
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Research Funding - AstraZeneca
Michael D Malone
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Research Funding - AstraZeneca
Jim W Growcott
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Darren R Hodgson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Robert Sloane
No relevant relationships to disclose
David J Moore
No relevant relationships to disclose
Tim H Ward
No relevant relationships to disclose
P. Anthony Elliott
Research Funding - AstraZeneca
Caroline Dive
No relevant relationships to disclose